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 18 
Abstract  19 
 20 
AICAR is the precursor of ZMP, a metabolite with anti-proliferative properties in yeast and 21 
human. We aim at understanding how AICAR (and its active form ZMP) affects essential 22 
cellular processes. In this work, we found that ZMP accumulation is synthetic lethal with a 23 
hypomorphic allele of the ubiquitin activating enzyme Uba1. A search for gene dosage 24 
suppressors revealed that ubiquitin overexpression was sufficient to restore growth of the 25 
uba1 mutant upon AICAR treatment, suggesting that the ubiquitin pool is critical for cells to 26 
cope with AICAR. Accordingly, two mutants with constitutive low ubiquitin, ubp6 and doa1, 27 
were highly sensitive to AICAR, a phenotype that could be suppressed by ubiquitin 28 
overexpression. We established, by genetic means, that these new AICAR-sensitive mutants 29 
act in a different pathway from the rad6/bre1 mutants which were previously reported as 30 
sensitive to AICAR (Albrecht et al., 2016). Two ubiquitin-conjugating enzymes (Ubc4 and 31 
Cdc34) and a ubiquitin ligase (Cdc4) were found to contribute to the ability of cells to cope 32 
with ZMP. This study illustrates the complexity of chemo-genetic interactions and shows how 33 
genetic analyses allow deciphering the implicated pathways, the individual gene effects and 34 
their combined phenotypic contribution. Based on additivity and suppression patterns, we 35 
conclude that AICAR treatment shows synthetic interactions with distinct branches of the 36 
yeast ubiquitin pathway.  37 
 38 
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 42 
INTRODUCTION  43 
ZMP, the monophosphate derivative of Amino-Imidazole CarboxAmide Ribonucleoside 44 
(AICAR), is a precursor of AMP in the purine de novo biosynthesis pathway (Fig. 1a) and as 45 
such is naturally present in cells at low concentrations (micro molar range, (Daignan-Fornier 46 
and Pinson, 2012; Hurlimann et al., 2011)). At higher concentrations, ZMP is a potent low-47 
energy mimetic which stimulates AMP-activated protein kinase (AMPK) by mimicking 48 
activation by AMP (Sullivan et al., 1994a; Sullivan et al., 1994b). In vivo, this AMPK 49 
activating effect was shown to increase endurance of sedentary mice (Narkar et al., 2008). At 50 
high concentrations, AICAR induces cell cycle arrest and/or apoptosis (Rattan et al., 2005). In 51 
vivo antitumor effects of AICAR have been reported in non-orthotopic mouse models (Guo et 52 
al., 2009; Liu et al., 2014; Rattan et al., 2005; Robert et al., 2009; Tang et al., 2011) and 53 
AICAR, also pharmacologically referred to as Acadesine, is considered as a potential 54 
antitumor agent. A Phase I/II study has been successfully conducted to determine the safety 55 
and tolerability of AICAR to treat patients with chronic lymphocytic leukemia (CLL) (Van 56 
Den Neste et al., 2013). We and others have shown that AICAR cytotoxicity was not affected 57 
in the absence of AMPK (Ceschin et al., 2014; Liu et al., 2014) indicating that AICAR has 58 
other important targets that could strongly contribute to its potential anti-tumor effects but 59 
could also cause unwanted side effects. In line with this remark, ZMP, the monophosphate 60 
derivative of AICAR is accumulated in several purine genetic diseases and could contribute to 61 
the poorly understood etiology of these diseases (Ceballos-Picot et al., 2015; Daignan-Fornier 62 
and Pinson, 2012). For all these reasons, understanding, how AICAR (and its active form 63 
ZMP) affects cellular processes and results in beneficial or an adverse effects, is crucial. 64 
To identify cellular functions affected by AICAR, we took advantage of yeast genetics to 65 
isolate and characterize several yeast mutants showing higher sensitivity to AICAR (Albrecht 66 
et al., 2016; Ceschin et al., 2015; Ceschin et al., 2014). Of note, search for AICAR-sensitive 67 
mutants cannot easily be done at a genome wide scale since a specific and complex genetic 68 
set-up (ade16 ade17 ade8 his1) is required to reveal AICAR-sensitivity (Fig. 1a) (Ceschin et 69 
al., 2015; Hurlimann et al., 2011). Recently, we found that sensitivity to AICAR is connected 70 
with the ubiquitin pathway in yeast and mammals. In particular, AICAR treatment is synthetic 71 
lethal with loss of function of several histone-modifying enzymes in yeast and human cells 72 
(Albrecht et al., 2016). Indeed, in yeast cells, the deletion of BRE1, that catalyzes the 73 
ubiquitination of H2B (H2Bub), results in a severe inhibition of growth under AICAR 74 
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treatment. Accordingly, the non-ubiquitinable form of H2B, H2BK123R, was also found to be 75 
highly sensitive to AICAR. It is well known that H2Bub is a signal of transactivation for two 76 
methyltransferases, Dot1 and Set1/COMPASS. We showed that a set1 mutant was exquisitely 77 
sensitive to AICAR, as was the non-methylable form of its targets H3K4. Remarkably, the 78 
knock-down of the corresponding orthologs, Rnf40 for Bre1, Ash2l and Mll4/KMT2D for 79 
COMPASS, were found to exacerbate AICAR sensitivity of human HCT116 cells (Albrecht 80 
et al., 2016). 81 
Here, we show that a mutation in the UBA1 gene encoding the yeast ubiquitin activating 82 
enzyme (E1) is synthetic lethal with AICAR treatment. This result prompted us to examine 83 
more systematically the connections between AICAR and the ubiquitin-pathway (Fig. 1b). 84 
We identified the ubiquitin pool as having a central role in AICAR sensitivity and established 85 
that mutants with reduced ubiquitin pools, such as ubp6 or doa1, are highly sensitive to the 86 
drug. Based on suppression patterns and additivity, these mutants were found to belong to a 87 
distinct branch of the ubiquitin-pathway which is required for yeast cells to cope with AICAR 88 
and acts in parallel to the Rad6/Bre1 branch identified previously (Albrecht et al., 2016). The 89 
complex chemo-genetic interactions between a metabolite and the ubiquitin pathway reported 90 
here, illustrate how poly-pharmacological effects can result in phenotypic synergy. 91 
 92 
Material and methods 93 
 94 
Yeast media  95 
SD is a synthetic minimal medium containing 0.5% ammonium sulfate, 0.17% yeast nitrogen 96 
base without amino acids and ammonium sulfate (BD-Difco), 2% glucose. SDcasaW is SD 97 
medium supplemented with 0.2% casamino acids (BD-Difco) and tryptophan (0.2 mM). 98 
When indicated, adenine (0.3 mM) and/or uracil (0.3 mM) were added in SDcasaW medium 99 
resulting in media named SDcasaWA (+ adenine), SDcasaWU (+ uracil) and SDcasaWAU (+ 100 
adenine + uracil). SC medium was prepared as described (Sherman, 1986). SC complete 101 
medium is SC medium supplemented with adenine (0.3 mM), uracil (0.3 mM), histidine (0.06 102 
mM), leucine (0.4 mM), lysine (0.06 mM) and tryptophan (0.2 mM).  103 
 104 
Strains and plasmids 105 
All yeast strains are listed in Table 1 and belong to, or are derived from, a set of disrupted 106 
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strains isogenic to BY4741 or BY4742 purchased from Euroscarf. Multi-mutant strains were 107 
obtained by crossing, sporulation and micromanipulation of meiosis progeny. For each cross, 108 
systematic tetrad analysis was done to verify correct segregation of the markers (mating type, 109 
auxotrophy, temperature sensitivity, PCR detection of KanMX4 knock-out…).  The presence 110 
of the uba1-o1 allele in the Y8033 strain used for gene dosage screening was verified by 111 
sequencing of the UBA1 locus. All plasmids used in this study are listed in Table 2 and were 112 
obtained by PCR amplification on genomic DNA and cloning in indicated vectors. Cloning 113 
details are available upon request. 114 
 115 
Growth test 116 
Overnight pre-cultured yeast cells were re-suspended in sterile water at 3.107 cells/ml and 117 
submitted to 1/10 serial dilutions. Drops (5 µl) of each dilution were spotted on freshly 118 
prepared medium plates and were incubated at indicated temperature for 48-72 h before 119 
imaging.  120 
 121 
Isolation of multicopy suppressors of the uba1-o1 AICAR-sensitive phenotype  122 
Multicopy suppressors of the ade16 ade17 ade8 his1 uba1-o1 AICAR-sensitive phenotype 123 
were obtained by transforming the Y8033 strain with a multicopy-plasmid library (PFL44L 124 
backbone, 2µ URA3; generous gift from F. Lacroute). Transformants selected on SDcasaWA 125 
medium at 25 °C were then replica-plated on the same medium containing or not AICAR (5 126 
mM) and plates were incubated for 1-3 days at 33 °C. As described in the Results section, we 127 
focused our attention on 5 clones containing ubiquitin-encoded genes: UBI4, RPL40A and 128 
RPL40B. Among those, the plasmid p4814 corresponded to a chromosome IX fragment 129 
(coordinates from 67814 bp to 71209 bp) containing RPL40A as the only entire gene. Three 130 
other plasmids contained fragments of chromosome XI with RPL40B as the only entire 131 
common gene. Finally, the fifth plasmid presented a fragment of chromosome XII 132 
(coordinates from 63188 bp to 67952 bp) containing 3 entire open reading frames (ORF): 133 
UBI4, ENT4 and YLL037w. Subcloning of the UBI4 ORF alone (P5504) in a YEplac195 134 
plasmid (Gietz and Sugino, 1988) allowed us to show that this ORF was sufficient for 135 
suppression of the AICAR-sensitive phenotype.  136 
 137 
Western blotting 138 
Total protein extraction was performed by disruption of exponential growing cells with glass-139 
beads in trichloro-acetic acid 5 %, as described in (Escusa et al., 2006). Protein extracts were 140 
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separated by SDS-PAGE, transferred onto 0.45 µ PVDF membrane and protein of interest 141 
were detected by western blotting using anti Act1 (generous gift from I. Sagot (Bordeaux, 142 
France), 1/100,000), anti-H2B (Active motif ; #39237, 11/2,000) or anti Ubi (Abcam, 143 
#ab19247 1/10,000). Blots Quantification was done with Image J (NIH). 144 
 145 
Results 146 
 147 
Synthetic lethality of a uba1 mutation with ZMP accumulation can be rescued by ubiquitin 148 
overexpression 149 
Our previous report establishing a connection between sensitivity to AICAR and the ubiquitin 150 
pathway (Albrecht et al., 2016) prompted us to examine whether sensitivity to AICAR could 151 
be affected under conditions where the ubiquitin-pathway is dysfunctional. We started with 152 
the UBA1 gene encoding the ubiquitin activating enzyme (E1) at the apex of the ubiquitin 153 
pathway, hence governing all the ubiquitin-dependent processes (McGrath et al., 1991). We 154 
asked whether accumulation of ZMP could lead to a synthetic phenotype when combined with 155 
a temperature sensitive allele (uba1-o1) of the UBA1 gene (Shimada et al., 2002). The uba1-156 
o1 mutant was mated to an ade16 ade17 double mutant which constitutively accumulates 157 
ZMP (Pinson et al., 2009) and meiosis of the resulting diploid was induced. Strikingly, in the 158 
meiotic progeny, no ade16 ade17 uba1-o1 triple mutant could be obtained at permissive 159 
temperature unless rescued by a plasmid expressing the wild-type UBA1 gene (Fig. 2a) thus 160 
revealing synthetic lethality between ade16 ade17 and uba1-o1. Importantly, this synthetic 161 
lethality could be totally abolished by ade8 and his1 mutations (Fig. 2b) blocking ZMP 162 
synthesis upstream of Ade16 and Ade17 (Fig. 1a) and thus eliminating ZMP accumulation 163 
(Hurlimann et al., 2011). Finally, in the uba1-o1 ade16 ade17 ade8 his1 mutant, the synthetic 164 
growth defect was recapitulated by addition of the ZMP-precursor AICAR at semi-permissive 165 
temperature (33°C), a condition that did not affect growth of the uba1-o1 ade16 ade17 ade8 166 
his1 mutant in the absence of AICAR (Fig. 2b). We conclude that the uba1-o1 mutant is 167 
synthetic lethal with ZMP accumulation supplied by two different means, either endogenously 168 
from the purine pathway (Fig. 2a) or exogenously from the growth medium (Fig. 2b). 169 
Together these results reveal that partial loss of function of the ubiquitin-conjugating enzyme 170 
Uba1 is synthetic lethal with ZMP accumulation. Hence, the ubiquitin pathway appears 171 
critical for yeast cells to cope with ZMP. 172 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
 
As a first step toward understanding how AICAR affects the ubiquitin pathway, we searched 173 
for gene-dosage suppressors that would restore growth of the uba1-o1 ade16 ade17 ade8 his1 174 
mutant in the presence of AICAR. A genomic multicopy plasmid library was transformed in 175 
the uba1-o1 ade16 ade17 ade8 his1 mutant and a set of 37 clones showing improved capacity 176 
to grow in the presence of AICAR at 33°C were studied. Among them no plasmid carrying 177 
the UBA1 gene was found suggesting that it was not present in the genomic library possibly 178 
because of the large size of the coding region >3kb. Indeed, in a reconstitution experiment, 179 
the growth defect was fully suppressed by a plasmid expressing UBA1 (not shown). Five 180 
plasmids contained either the ADE16 (3 clones) or the ADE17 (2 clones) gene, thus restoring 181 
ATIC enzymatic activity and preventing ZMP accumulation. These plasmids were not further 182 
studied. Among the remaining clones, we only studied those carrying a single chromosome 183 
fragment and presenting a robust suppression phenotype after retransformation. Eleven such 184 
plasmids revealed DDP1 (1 clone), ECM21 (1 clone), RPL40A (1 clone), RPL40B (3 clones), 185 
UBI4 (1 clone) and URA6 (4 clones) as gene-dosage suppressors after individual subcloning 186 
(Fig. 2c). DDP1 encodes an inositol polyphosphate phosphatase, ECM21 encodes an arrestin 187 
and URA6 a uridylate kinase. The three remaining genes, UBI4, RPL40A and RPL40B, encode 188 
precursors of free ubiquitin (Finley et al., 1989; Finley et al., 1987) and were therefore 189 
directly related to UBA1 function as the ubiquitin-activating enzyme. We focused on those in 190 
the rest of the work. We conclude that overexpression of ubiquitin allows bypassing of 191 
AICAR sensitivity of the uba1-o1 ade16 ade17 ade8 his1 mutant. This result suggested that 192 
the ubiquitin pool could play an important role in AICAR sensitivity in yeast. Importantly, the 193 
free-ubiquitin pool was significantly higher in the uba1-o1 mutant than in the control strain 194 
(Fig. 2d, arrow) indicating that the exacerbated sensitivity of the uba1-o1 mutant to AICAR is 195 
not due a lower pool of free-ubiquitin. In both wild-type and uba1-o1 strains overexpression 196 
of UBI4 resulted in increased free-ubiquitin (Fig. 2d), though the amount of free ubiquitin was 197 
higher in the uba1-o1 mutant possibly reflecting its defective utilization by the E1 mutant 198 
enzyme. In both strains, UBI4 overexpression strongly increased the signal of ubiquitylated 199 
proteins indicating that under physiological conditions ubiquitin synthesis limits the 200 
ubiquitylation process. Finally, we found no effect of AICAR treatment on the ubiquitin pool 201 
(Fig. 2d). From these results, we conclude that AICAR-sensitivity of the uba1-o1 ade16 202 
ade17 ade8 his1 mutant is not associated to a lower free-ubiquitin pool due to the mutation or 203 
to AICAR treatment, but rather to a defect in the ubiquitylation process that can be efficiently 204 
suppressed by overexpressing ubiquitin. We interpret these results as an indication that, in the 205 
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uba1-o1 ade16 ade17 ade8 his1 mutant, a function aggravated by AICAR treatment can be 206 
rescued by ubiquitin overexpression. 207 
 208 
Mutants with reduced ubiquitin pools are highly sensitive to AICAR but do not recapitulate 209 
the rad6/bre1 phenotypes 210 
We next asked whether AICAR treatment itself could impose an enhanced demand for 211 
ubiquitin that would be exacerbated by the uba1 mutation to a point leading to the observed 212 
AICAR-hypersensitivity of this mutant. Several yeast mutants such as, doa1 and ubp6, have 213 
constitutively reduced free-ubiquitin pools, due to defective ubiquitin recycling (Amerik et 214 
al., 2000; Johnson et al., 1995). The doa1 and ubp6 knock-out mutations were introduced in 215 
the ade16 ade17 ade8 his1 background allowing controlled accumulation of ZMP as a result 216 
of feeding with AICAR (Hurlimann et al., 2011). Both mutations were found to lower the 217 
ubiquitin pool (Fig. 3a) as previously reported (Amerik et al., 2000; Johnson et al., 1995) and 218 
to severely impair growth of yeast cells in the presence of AICAR (Fig. 3b). Importantly this 219 
growth defect could be robustly suppressed by overexpression of UBI4 (Fig. 3b), indicating 220 
that the low pool of ubiquitin was implicated in the exacerbated AICAR sensitivity of these 221 
mutants.  222 
We then examined whether the chemo-genetic interaction between AICAR and the doa1 or 223 
ubp6 mutants was phenocopying the previously described synthetic lethality between ZMP 224 
and the rad6 or bre1 mutants (Albrecht et al., 2016). Indeed, in a previous work, we found 225 
that the ubiquitin conjugating enzyme Rad6 together with the ubiquitin ligase Bre1 were 226 
critical for yeast cells to grow in the presence of AICAR (Albrecht et al., 2016). This growth 227 
defect resulted from the lack of ubiquitylation of histone H2B in the absence of Rad6/Bre1 228 
together with a cell cycle default associated to defective entry of the cyclin Cln3 in the 229 
nucleus due to AICAR treatment (Albrecht et al., 2016). Since free ubiquitin is present in 230 
limiting amounts in cells, changes in the ubiquitin pool directly affect ubiquitin modifications 231 
(Groothuis et al., 2006) (Fig. 2d) and accordingly the free ubiquitin pool was found to impact 232 
on histone ubiquitination in mammalian cells (Dantuma et al., 2006). Hence, we suspected 233 
that doa1 and ubp6 mutants could directly affect H2B ubiquitination. Indeed, doa1 and ubp6 234 
mutants showed a decreased ubiquitination of H2B that could be restored by UBI4 235 
overexpression (Fig. 3c). These results suggested that low-ubiquitin mutants could be 236 
sensitive to AICAR in part because of the reduced ubiquitylation of H2B that could mimic the 237 
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bre1 or rad6 phenotype. This assumption was directly assessed by genetic means, i.e. by 238 
comparing their suppression pattern. The rationale here was that if doa1 and ubp6 mutants are 239 
sensitive to AICAR because they mimic rad6 or bre1, they should be suppressed by the same 240 
suppressors. As previously reported (Albrecht et al., 2016), CLN3 overexpression could 241 
efficiently suppress the AICAR growth-defect of the bre1 mutant (Fig. 3b), however it had 242 
little or no effect on ubp6 or doa1 mutations (Fig. 3b). We conclude that part of the effects of 243 
ubp6 or doa1 mutations are likely due to their lower ability to ubiquitylate H2B, but that a 244 
remaining part of their effect is independent of Rad6/Bre1 and can be suppressed by 245 
increasing cellular ubiquitin (Fig. 3B). These results suggested that another effector in the 246 
ubiquitin pathway was involved. We then aimed at identifying this effector. 247 
 248 
Genetic analysis reveals new E2 and E3 AICAR-sensitive mutants 249 
Ubiquitin once activated by Uba1 is conveyed to ubiquitin-conjugating enzymes (E2s), which 250 
in turn, with or without the help of specific ubiquitin ligases (E3s), transfer the ubiquitin 251 
moiety to the target proteins (Fig. 1b). In yeast there are 11 E2s and dozens of E3s (Finley et 252 
al., 2012). To further explore how AICAR affects the ubiquitylation pathway downstream of 253 
Uba1 (E1), we started with a systematic genetic analysis of the ubiquitin conjugating enzymes 254 
(E2s). Among the eleven yeast E2s, nine are encoded by non-essential genes (Finley et al., 255 
2012). The corresponding knock-out mutations were combined with the ade16 ade17 ade8 256 
his1 mutations allowing ZMP accumulation in yeast when yeast cells are fed with AICAR 257 
(Hurlimann et al., 2011). While most E2 mutations did not affect the sensitivity to AICAR 258 
accumulation (Fig. 4a), the rad6 (ubc2) knock-out strongly altered growth in the presence of 259 
AICAR (Fig. 4a), thus confirming our previous report (Albrecht et al., 2016). In addition, 260 
ubc4 was also sensitive to AICAR accumulation (Fig. 4a) although to a lesser extent. Ubc4 is 261 
known to be involved in protein degradation. In particular, Ubc4 coupled with Not4 poly-262 
ubiquitinates the H3K4 demethylase, Jhd2, leading to its degradation (Mersman et al., 2009). 263 
Thus, Jhd2 stabilization in the ubc4 mutant would lead to lower H3K4 methylation (Mersman 264 
et al., 2009) hence phenocopying a defect in H3K4 methylation by Set1. Since Set1 265 
methylation of H3K4 is dependent on H2B ubiquitylation by Rad6/Bre1 (Nakanishi et al., 266 
2009) a defective Ubc4 should mimic the rad6/bre1 defect and should show the same 267 
suppression pattern. Indeed, the ubc4 mutant growth defect in the presence of AICAR was 268 
robustly suppressed by CLN3 overexpression but not by UBI4 (Fig. 4b), hence phenocopying 269 
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a bre1 mutant (Fig. 3d). This result thus phenotypically positioned the ubc4 mutant in the 270 
“rad6/bre1/set1 pathway”.  271 
We then examined the effect of a defect in the two remaining essential E2s, Ubc1 and 272 
Ubc3/Cdc34, on AICAR sensitivity. We found that, in the S288c background, UBC1 is 273 
essential for germination but not for vegetative growth and we could thus construct a viable 274 
ade16 ade17 ade8 his1 ubc1 quintuple mutant. Clearly, ubc1 knock-out did not affect growth 275 
in the presence of AICAR (Fig. 4c) (compared to set1 shown here as an AICAR-sensitive 276 
control). For cdc34, AICAR-sensitivity was assayed on a temperature sensitive allele cdc34-2 277 
(Liu et al., 1995) at semi-permissive temperature. The cdc34-2 mutant was highly sensitive to 278 
endogenous ZMP accumulation (Fig. 4d) or AICAR as an exogenous source of ZMP (Fig. 279 
4e). Cdc34 catalyzes substrate ubiquitination via the Skp1-Cullin-F-box (SCF) ubiquitin 280 
protein ligase complex in which the F-box proteins function as substrate-specific adaptors 281 
(Feldman et al., 1997; Goebl et al., 1988; Skowyra et al., 1997). Cdc4 is one of these F-box 282 
proteins and we asked whether it would be required for growth under conditions leading to 283 
ZMP accumulation. The cdc4-3 mutation was highly sensitive to ZMP accumulation whether 284 
it was from an internal source (ade16 ade17 background; Fig. 4f) or upon AICAR feeding 285 
(ade16 ade17 ade8 his1 background; Fig. 4g). We conclude that Cdc34 and Cdc4 define a 286 
new ubiquitin sub-pathway required for cells to cope with AICAR. 287 
 288 
Suppression and additivity patterns unveil complex interactions between ZMP and the 289 
ubiquitin pathway 290 
Phenotypic suppression of the newly identified cdc34 and cdc4 mutants by increased gene 291 
dosage of CLN3 or UBI4 was evaluated. The AICAR sensitivity of the cdc34-2 mutant was 292 
suppressed by overexpression of UBI4 but not by CLN3 (Fig. 5a). By contrast, cdc4-3 was 293 
slightly suppressed by CLN3 but not by UBI4 increased gene dosage (Fig. 5b-c). Finally, 294 
CLB5 a known dosage suppressor of cdc4 (Cui et al., 2002) indeed suppressed the high 295 
sensitivity to AICAR of the corresponding cdc4-3 temperature sensitive mutants (Fig. 5c) but 296 
also that of a cdc34-2 mutant (Fig. 5d). Still, CLB5 overexpression had no effect on AICAR-297 
sensitivity of the bre1, set1, doa1, ubp6 and uba1-o1 mutants (Fig. 5e-i). Thus based on gene-298 
dosage suppression patterns, we can distinguish the various mutants of the ubiquitin pathway 299 
leading to AICAR sensitivity (Fig. 6). A simple assumption derived from this model is that 300 
mutations affecting the distinct “branches” should have additive effects. This was assayed by 301 
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constructing a bre1 ubp6 strain capable of accumulating ZMP upon AICAR feeding (ade16 302 
ade17 ade8 his1 background). We found that the bre1 ubp6 mutant was much more sensitive 303 
to AICAR than a bre1 or an ubp6 strain alone at low AICAR concentration (2 mM, Fig. 7a). 304 
This additivity indicates that the chemo-genetic interaction of these two mutants with AICAR 305 
involves different functions. Accordingly, UBI4 overexpression could still suppress a part, but 306 
not all, of the sensitivity to AICAR of the bre1 ubp6 strain, resulting in a level of AICAR-307 
sensitivity equivalent to that of a single bre1 mutant (Fig. 7a). Additivity was also found for 308 
the set1 and doa1 mutations (Fig. 7b) confirming the idea that these mutations result in 309 
AICAR sensitivity through different means as deduced from their suppression pattern (Fig. 6). 310 
Finally, co-overexpression of CLN3 and UBI4 in the uba1-o1 mutant showed an additive 311 
suppression effect (Fig. 7c) indicating that the uba1 mutation affects both downstream 312 
branches, as expected for a mutation affecting the enzyme which is at the apex of the 313 
ubiquitin pathway. Interestingly, the uba1-o1 mutant exhibited a strong defect in H2B 314 
ubiquitination at semi-permissive temperature and this could be restored by UBI4 315 
overexpression (Fig. 7d). Hence, while UBI4 overexpression restored H2B ubiquitylation, it 316 
only partially suppressed the uba1-o1 growth phenotype (Fig. 7c) suggesting that the 317 
Rad6/Bre1 branch might affect one or several other targets than H2B that would be 318 
suppressed by CLN3 overexpression but not or only partially by UBI4 overexpression. We 319 
conclude that ZMP accumulation results in multiple chemo-genetic interactions with the 320 
ubiquitin pathway in yeast, thus illustrating the complexity of drug action and the helpfulness 321 
of genetics to address it. 322 
 323 
DISCUSSION  324 
In a previous work we identified histone ubiquitylation mutants as synthetic lethal with 325 
AICAR treatment (Albrecht et al., 2016). Here we further uncovered phenotypic interactions 326 
between AICAR/ZMP and the ubiquitin pathway and identified several new mutants (uba1, 327 
ubc4, cdc34, cdc4, ubp6 and doa1) showing exacerbated sensitivity to AICAR. Differential 328 
patterns of gene dosage suppression as well as phenotypic additivity revealed that these 329 
mutants affect distinct branches, hence suggesting that AICAR interferes with one or several 330 
functions particularly required when the ubiquitin pathway is impaired. Among the mutants 331 
studied here and in our previous study, uba-o1 was the only one resulting in synthetic lethality 332 
with the ade16 ade17 mutations leading to constitutive ZMP accumulation as revealed by our 333 
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inability to recover viable spores. This pronounced sensitivity could reflect the fact that Uba1 334 
(E1) is at the apex of the ubiquitin pathway and therefore conditions all downstream ubiquitin 335 
reactions. Among the 11 ubiquitin conjugating enzyme (E2) mutants, three (rad6, ubc4 and 336 
cdc34) were affected by the drug hence revealing the major pathways downstream of Uba1 337 
that are required for yeast cells to resist AICAR. Following-up on Cdc34, we could identify 338 
the Cdc4 ubiquitin ligase (E3) as required for AICAR tolerance. 339 
Why is AICAR toxic for ubiquitin pathway mutants? We have shown in this work that the 340 
abundance of ubiquitin itself is an important factor in the drug toxicity though we 341 
demonstrated that AICAR does not directly affect it. Clearly in the case of doa1 and ubp6 it is 342 
the low ubiquitin pool that is responsible for the exacerbated toxicity of AICAR. It is likely 343 
that more than one function is involved in the phenotype and indeed these mutants were not 344 
efficiently suppressed by overexpression of neither CLN3 nor CLB5. For cdc34 and cdc4, 345 
both mutants were suppressed by CLB5 overexpression, while this was not the case for the 346 
other AICAR-sensitive mutants, suggesting that a negative effector stabilized in these mutants 347 
could be displaced by CLB5 overexpression. It remains to be established whether the multiple 348 
connections, between AICAR and the ubiquitin pathway, revealed here, are more than 349 
serendipitous i.e. whether there is a common target that when affected by ZMP results in 350 
synthetic toxicity with the various ubiquitin mutants. The fact, that up to now, we identified 351 
no common gene dosage suppressor to the various mutants, does not support this hypothesis. 352 
However, Uba1 was found among ZMP-binders by affinity chromatography (our unpublished 353 
results) and could therefore be a direct and central target. In any case, the strong connections 354 
between AICAR and the ubiquitin pathway could be highly relevant to understand why 355 
AICAR selectively inhibits proliferation of aneuploid cells (Tang et al., 2011). Indeed, 356 
aneuploidy is known to result in proteotoxicity (Donnelly and Storchova, 2015; Santaguida 357 
and Amon, 2015) and as such could impose a strong demand on the ubiquitin pathway. This 358 
work thus provides a lead for further work on AICAR selective effects on aneuploid cells.  359 
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Tables  487 
Table 1 Yeast strains used in this study 488 
 489 
Strain Genotype  References 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Euroscarf 
BY4742 MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 Euroscarf 
Y1093 MATa his3Δ1 leu2Δ0 ura3Δ0 ade16::KanMX4 ade17::KanMX4 (Hurlimann 
et al., 
2011) 
Y1162 MATα his3Δ1 leu2Δ0 ura3Δ0 ade16::KanMX4 ade17::KanMX4 (Hurlimann 
et al., 
2011) 
Y2950 MATα his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 
(Pinson et 
al., 2009) 
Y3273 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cdc4-3 (Li et al., 
2011) 
Y3275 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cdc34-2 (Li et al., 
2011) 
Y6853 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 uba1-o1 (Li et al., 
2011) 
Y6987 MATα his3Δ1 leu2Δ0 ura3Δ0 uba1-o1 This study 
Y7070 MATa his3Δ1 leu2Δ0 ura3Δ0 ade17::KanMX4 uba1-o1 This study 
Y7071 MATα his3Δ1 leu2Δ0 ura3Δ0 ade16::KanMX4 uba1-o1 This study 
Y7117 MATa his3Δ1 leu2Δ0 ura3Δ0 ade16::KanMX4 ade17::KanMX4 
uba1-o1 [ptet-UBA1] 
This study 
Y8033 MATa his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 uba1-o1 [ptet-empty, CEN LEU2] 
This study 
Y8385 MATa his3Δ1 leu2Δ0 ura3Δ0 ade16::KanMX4 ade17::KanMX4 
cdc4-3 
This study 
Y8406 MATa his3Δ1 leu2Δ0 ura3Δ0 ade16::KanMX4 ade17::KanMX4 
cdc34-2 
This study 
Y8675 MATα his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 can1::KanMX4 cdc4-3  
This study 
Y8679 MATα his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 cdc34-2  
This study 
Y9168 MATα his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ade8::KanMX4 
ade16::KanMX4 ade17::KanMX4 his1::KanMX4 set1::KanMX4 
(Albrecht 
et al., 
2016) 
Y9217 MATa his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 ade8::KanMX4 
ade16::KanMX4 ade17::KanMX4 his1::KanMX4 
rad6(ubc2)::KanMX4 
This study 
Y9516 MATα his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 This study 
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ade17::KanMX4 his1::KanMX4 bre1::kanMX4 
Y9915  MATα his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 ubc11::URA3 
This study 
Y9923 MATa his3Δ1 leu2Δ0 lys2Δ0  ura3Δ0 ade8::KanMX4 
ade16::KanMX4 ade17::KanMX4 his1::KanMX4 ubc5::KanMX4 
This study 
Y9925 MATα his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 ubc10::URA3 
This study 
Y9929 MATα his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 ubc13::URA3 
This study 
Y9931 MATa his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 ubc8::URA3 
This study 
Y9964 MATa his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 ubc7::KanMX4 
This study 
Y10034 MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 ade8::KanMX4 
ade16::KanMX4 ade17::KanMX4 his1::KanMX4 ubc6::LEU2 
This study 
Y10072 MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 ade8::KanMX4 
ade16::KanMX4 ade17::KanMX4 his1::KanMX4 ubc4::KanMX4 
This study 
Y10296 MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ade8::KanMX4 
ade16::KanMX4 ade17::KanMX4 his1::KanMX4 ubp6::KanMX4 
This study 
Y10524 MATα his3Δ1 leu2Δ0 ura3Δ0 trp1::LEU2 ade8::KanMX4 
ade16::KanMX4 ade17::KanMX4 his1::KanMX4 set1::URA3 
This study 
Y10696 MATa his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 doa1::KanMX4 
This study 
Y10757 MATa his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 ade8::KanMX4 
ade16::KanMX4 ade17::KanMX4 his1::KanMX4 bre1::KanMX4 
ubp6::KanMX4 
This study 
Y10817 MATα his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ubc1::KanMX4 This study 
Y10840 MATα his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 ubc1::KanMX4 
This study 
Y11352 MATa his3Δ1 leu2Δ0 ura3Δ0 ade8::KanMX4 ade16::KanMX4 
ade17::KanMX4 his1::KanMX4 uba1-o1  
This study 
Y11389 MATa his3Δ1 leu2Δ0 trp1::LEU2 ura3Δ0 ade8::KanMX4 
ade16::KanMX4 ade17::KanMX4 his1::KanMX4 doa1::KanMX4 
set1::URA3 
This study 
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Table 2 Plasmid used in this study 492 
 493 
Plasmid  Backbone characteristics Sources 
pCM189 pCM189 CEN ARS URA3 tet-OFF promoter (Gari et 
al., 1997) 
pFL44L pFL44L 2 micron URA3 (Bonneaud 
et al., 
1991) 
YCpLac111 YCplac111 CEN ARS LEU2 (Gietz and 
Sugino, 
1988) 
YEpLac 181 YEpLac 181 2 micron LEU2 (Gietz and 
Sugino, 
1988) 
YEpLac 195 YEpLac 195 2 micron URA3 (Gietz and 
Sugino, 
1988) 
p4515 pCM189 CEN ARS URA3 tet-OFF promoter-UBA1 This study 
p4742 YEpLac 195 CLN3 2 micron URA3 (Albrecht 
et al., 
2016) 
p4807 pFL44L 2 micron URA3 RPL40B PTR2 This study 
p4814 pFL44L 2 micron URA3 RPL40A This study 
p4859 YEpLac 195 2 micron URA3 DDP1 This study 
p4919 YEpLac 195 2 micron URA3 URA6 This study 
p4943 YCplac111 UBA1 CEN ARS LEU2 This study 
p5183 pFL44L 2 micron URA3 ECM21 This study 
p5504 YEpLac 195 UBI4 2 micron URA3 This study 
p5516 YEpLac 181 UBI4 2micron LEU2 This study 
p5791 YEpLac 195 CLB5 2 micron URA3 This study 
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Legend of figures 495 
 496 
Fig. 1 Schematic representation of the de novo purine and histidine pathways (a) and the 497 
ubiquitin cascade (b) in yeast. a Only the enzymes mentioned in the text are shown (in green). 498 
AICAR: 5-Amino-Imidazole 4-CarboxAmide Ribonucleoside; AMP: adenosine 5'-499 
monophosphate; GMP: Guanosine 5'-monophosphate; IMP: Inosine 5'-monophosphate; 500 
PRPP: α-D-ribofuranose 5-phosphate 1-diphosphate; ZMP: AICAR monophosphate. b E1, E2 501 
and E3 stand for ubiquitin-activating enzyme, ubiquitin-conjugating enzymes and ubiquitin-502 
protein ligases, respectively. Target: protein target. Ub: ubiquitin.  503 
 504 
Fig. 2 AICAR toxicity in the hypomorphic uba1-o1 mutant is alleviated by ubiquitin 505 
overexpression. a The ade16 ade17 uba1-o1 is viable only if UBA1 is ectopically expressed. 506 
Wild-type (BY4742) and mutant (ade16 ade17: Y1093; uba1-o1: Y6853; ade17 uba1-o1: 507 
Y7070; ade16 uba1-o1: Y7071 and ade16 ade17 uba1-o1: Y7117) strains containing a 508 
plasmid allowing expression of UBA1 gene under the control of a doxycycline-repressible 509 
promoter (p4515) were grown on SDcasaWA medium containing (+) or not (-) doxycycline 510 
(Dox;100 mg/l). b Growth of the uba1-o1 mutant is impaired at semi-permissive temperature 511 
when ZMP is accumulated by exogenous addition of its riboside precursor AICAR in the 512 
ade8 ade16 ade17 his1 (Quad) genetic background. Strains (Y6987, Y2950 and Y8033) were 513 
grown for 48 hours at indicated temperatures on SDcasaWAU medium containing or not 514 
AICAR (10 mM). c Overexpression of gene-dosage suppressors restored growth of the uba1-515 
o1 mutant in the presence of AICAR. The ade8 ade16 ade17 his1 uba1-o1 quintuple mutant 516 
was transformed with plasmids allowing overexpression of indicated genes (ECM21: p5183; 517 
URA6: p4919; DDP1: p4859; RPL40B: p4807; RPL40A: p4814 and UBI4: p5504) or with an 518 
empty vector (YepLac195). Growth of transformants was scored for 72 h at 32°C on 519 
SDcasaWA medium in the presence or not of AICAR (6 mM). d Free ubiquitin and ubiquitin-520 
conjugated signals were strongly increased when UBI4 gene is overexpressed (OE). Strains 521 
(Y2950 and Y8033) were transformed with a plasmid allowing UBI4 overexpression (p5504) 522 
or the cognate empty vector (YEplac195). Total protein extracts were prepared from 523 
transformants, overexpressing (+) or not (-) UBI4, grown in SDcasaWA medium and treated 524 
(+) or not (-) for 2 hours with AICAR (1 mM). Proteins were revealed by western blotting 525 
with anti-Ubi and anti-Act1 antibodies. Arrow points to free ubiquitin. Expo: Overexposure of 526 
the dashed box region revealed with anti-Ubi antibody.  527 
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Fig. 3 Mutants with low ubiquitin are highly sensitive to AICAR. a Conjugated ubiquitin is 529 
drastically decreased in ubp6 and doa1 mutants. Total protein extracts were obtained from 530 
strains (Y2950 (Control), Y10296 and Y10696) grown in SDcasaWAU medium, separated by 531 
SDS-page and ubiquitin-conjugated proteins were revealed by western blotting with an anti-532 
ubiquitin antibody. Act1 was used as a loading control. b Overexpression of UBI4 is 533 
sufficient to restore growth of the ubp6 and doa1 mutants in the presence of AICAR. Yeast 534 
strains (Y2950 (Control), Y10696, Y10296 and Y9168) were transformed with plasmids 535 
allowing overexpression (OE) of either UBI4 (p5504) or CLN3 (p4742), or with the empty 536 
vector (none, YEpLac195). Transformants were grown at 37 °C for 48 h on SDcasaWA 537 
medium containing or not AICAR (2 mM). c Ubiquitylation of H2B is increased when UBI4 538 
is overexpressed (OE). Total protein extracts were obtained on transformants from Fig. 3b. 539 
H2B pools were revealed by western blotting using an anti-H2B antibody. Act1 was used as a 540 
loading control. Quantifications were set at 1 for the control strain transformed with the empty 541 
vector (-). ND: not detectable. 542 
 543 
Fig. 4 Different “ubiquitin sub-pathways” are required for yeast to cope with AICAR toxicity. 544 
a Systematic analysis of AICAR-sensitivity of ubiquitin-conjugating enzyme (E2) mutants. 545 
Control (Y2950) and mutant (Y9217, Y10072, Y9923, Y10034, Y9964, Y9931, Y9925, 546 
Y9915 and Y9929) strains were grown in SDcasaWAU medium for 48 h at 30°C in the 547 
presence or absence of AICAR. b The AICAR-growth defect of ubc4 mutant is suppressed by 548 
CLN3 but not UBI4 overexpression. Strains (Y2950, Y10072) were transformed with 549 
plasmids overexpressing either CLN3 or UBI4, or by the empty vector (none). Transformants 550 
were grown in SDcasaWA medium for 48 h at 30°C. c AICAR-sensitivity is not affected in 551 
an ubc1 deletion mutant. Strains (Y10817, Y2950: control, Y10840, Y9168) were grown for 552 
48 h at 30°C on SDcasaWAU medium containing or not AICAR. d,f Growth of the cdc34-2 553 
(d) and the cdc4-3 (f) mutants is severely impaired by endogenous ZMP accumulation. 554 
Strains (Y1162, Y3273, Y3275, Y8385 and Y8406) were grown for 48 h on SDcasaWAU 555 
medium. e,g The cdc34-2 (e) and cdc4-3 (g) mutants are highly sensitive to AICAR treatment. 556 
Strains were grown for 48 h at 32 °C on SDcasaWAU medium containing or not AICAR.  557 
 558 
Fig. 5 Gene-dosage suppression of AICAR-sensitivity of the cdc4-3 and cdc34-2 mutants. 559 
Yeast strains (Y8679 (a, d), Y8675 (b, c), Y9516 (e), Y9168 (f), Y10696 (g), Y10296 (h) and 560 
Y8033 (i)) were transformed with plasmids allowing overexpression (OE) of either CLB5 561 
(p5791), CLN3 (p4742) or UBI4 (p5504) genes, or with an empty plasmid (YEpLac195, 562 
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none). In all panels, transformants were grown on SDcasaWA medium containing or not 563 
AICAR at 30°C (b) 32°C (c, i), 33°C (a, d) or 37°C (e-h).  564 
 565 
 566 
Fig. 6 Schematic representation of the “ubiquitin sub-pathways” revealed by gene-dosage 567 
suppression of the AICAR-sensitivity. Mutant names in white-bold letters correspond to the 568 
AICAR-sensitive or -insensitive mutants characterized in this study.   569 
 570 
Fig. 7 Combination of AICAR-sensitive mutants and gene dosage suppressors revealed 571 
complex genetic relationships between AICAR-sensitivity and ubiquitin pathways. a The 572 
double ubp6 bre1 mutant is hypersensitive to AICAR treatment. Yeast strains (Y10757, 573 
Y2950, Y9516 and Y10296) were transformed with the UBI4 overexpressing plasmid or the 574 
empty vector (none). Transformants were grown on SDcasaWA medium at 37°C for 48 h. b 575 
Additive AICAR sensitivity was observed by combining set1 and doa1 mutations. Strains 576 
(Y2950, Y10696, Y10524 and Y11389) were grown in SDcasaWAU medium for 72 h at 577 
37°C. (c) Double CLN3 and UBI4 overexpression is required to restore growth of the ade8 578 
ade16 ade17 his1 uba1-o1 in the presence of AICAR. Yeast strain (Y11352) was co-579 
transformed with plasmids overexpressing or not (empty vectors) CLN3 and UBI4 genes. 580 
Transformants were grown for 72 h on SC medium lacking leucine and uracil. (d) The 581 
ubiquitylation-defect of H2B in the ade8 ade16 ade17 his1 uba1-o1 is restored by UBI4 582 
overexpression. Yeast strains (Y2950, Y8033 and Y9516) were transformed with a plasmid 583 
overexpressing UBI4 (+) or the cognate empty vector (-). Total protein extracts were obtained 584 
on transformants grown in SDcasaWA medium at 32 °C and treated (+) or not (-) with 585 
AICAR (1 mM; 2 h). H2B and Act1 (loading control) were revealed by western blotting. 586 
Quantification was set at 1 for the control strain transformed with the empty vector (-). ND: 587 
not detectable. 588 
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